Gene Signal reports GS-101 data

Gene Signal S.A.S. (Lausanne, Switzerland) said interim data showed 86 ug/day of topical GS-101 met the primary endpoint vs. placebo in a Phase II trial to treat corneal neovascularization. Specifically, 86 ug/day of the antisense oligonucleotide reduced corneal neovascularization by producing a mean decrease from baseline in vascularized area of 2.04% (+/- 1.57) at three months (p=0.0047). Two other dosages -- 43 and 172 ug/day -- of the compound did not demonstrate a significant difference in the double-blind study in 40 patients. Data were published in Ophthalmology. ...